WEBULL
WebtradeDownload

Eli Lilly (LLY) Eyes Merida Deal As Trial Data Strengthens Autoimmune Push

Simply Wall St · 1d ago
  • Eli Lilly (NYSE: LLY) plans to acquire Merida Biosciences to expand its autoimmune and allergic disease pipeline, including lead candidate MER511.
  • The deal is expected to add early stage precision immunology assets to Lilly's existing portfolio in metabolic and neurology treatments.
  • New Phase 3b TOGETHER trial data report durable 52 week efficacy for a Taltz and Zepbound combination in patients with psoriatic disease and obesity.
  • The dual therapy approach targets both psoriatic disease activity and metabolic outcomes, highlighting Eli Lilly's push in immunometabolism.

These moves point to a broader shift toward data driven immunology and metabolic care that many investors are watching, and it can be useful to compare Eli Lilly's direction with companies working at the intersection of healthcare and AI through 39 healthcare AI stocks.

NYSE:LLY Earnings & Revenue Growth as at Sep 2026
NYSE:LLY Earnings & Revenue Growth as at Sep 2026

Eli Lilly is a US based pharmaceuticals company with a US$1.0 trillion market cap that discovers, develops, manufactures, and markets human medicines across major regions including the United States, Europe, China, and Japan. This autoimmune and metabolic push fits within a broader portfolio that already spans metabolic and neurology treatments.

We've flagged 1 risk for Eli Lilly. See which could impact your investment.

How this Eli Lilly deal tests the GLP-1 heavy Narrative

The current Eli Lilly Narrative assumes GLP-1 leadership is the main engine, with specialty drugs and precision therapies providing a second leg of growth and helping reduce concentration risk. This autoimmune deal and the Taltz and Zepbound data speak directly to that supporting leg.

"Ongoing innovation in high-value specialty drugs (including next-gen oral and injectable GLP-1, new indications, and precision therapies) and prudent capital allocation ..."

Read the full Eli Lilly narrative to see the case behind these numbers.

The Merida Biosciences acquisition leans into that specialty and precision-therapy theme. It adds early-stage autoimmune assets that sit outside pure incretin exposure, which is relevant given analysts have flagged risks around reliance on a narrow group of blockbuster GLP-1 drugs and policy-driven pricing pressure similar to what Novo Nordisk also faces.

The TOGETHER trial results matter because they show Eli Lilly trying to turn GLP-1 success into broader immunometabolic treatment platforms rather than isolated obesity drugs. That supports the Narrative idea of cardiometabolic and specialty therapies working together, but also raises the question of how much R&D and balance sheet capacity Eli Lilly wants to keep tying back to incretin-led combinations.

This acquisition and trial update only really matter when viewed against the kind of Eli Lilly story you believe, whether it is a GLP-1 centric giant or a more diversified immunology and neuroscience group.To ensure you're always in the loop on how the latest news impacts the investment narrative for Eli Lilly, head to the community page for Eli Lilly to never miss an update on the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.